Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 808 Precursor Cell Lymphoblastic Leukemia-Lymphoma 171 Recurrence 141 Neoplasms, Plasma Cell 111 Lymphoma 93 Leukemia 91 Neoplasms 81 Burkitt Lymphoma 57 Vomiting 51 Lymphoma, Non-Hodgkin 50 Immunoglobulin Light-chain Amyloidosis 50 Lymphoma, Large B-Cell, Diffuse 44 Nausea 38 Lymphoma, Mantle-Cell 38 Prostatic Neoplasms 31 Lymphoma, Follicular 30 Hodgkin Disease 29 Waldenstrom Macroglobulinemia 27 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 27 Neoplasm Metastasis 26 Leukemia, Lymphocytic, Chronic, B-Cell 26 Carcinoma, Non-Small-Cell Lung 26 Leukemia, Myeloid, Acute 25 Breast Neoplasms 25 Lung Neoplasms 23 Amyloidosis 21 Leukemia, Biphenotypic, Acute 18 Lymphoma, B-Cell, Marginal Zone 17 Lymphoma, Extranodal NK-T-Cell 16 Smoldering Multiple Myeloma 15

Interventions

sodium thiosulfate 4 Cisplatin 4 Methotrexate 2 Chemotherapy, Adjuvant 2 Acetylcysteine 2 tempol 1 ebselen 1 Vorinostat 1 Vincristine 1 Thioctic Acid 1 Surveys and Questionnaires 1 Sodium Chloride 1 Restraint, Physical 1 Radiotherapy, Intensity-Modulated 1 Radiotherapy, Conformal 1 Radiotherapy 1 Radiosurgery 1 Pantoprazole 1 Mental Status and Dementia Tests 1 Magnetic Resonance Spectroscopy 1 Hydroxymethylglutaryl-CoA Reductase Inhibitors 1 Hyaluronic Acid 1 Hearing Tests 1 Genetic Association Studies 1 Drug Therapy 1 Dexamethasone 1 Cyclophosphamide 1 Chemoradiotherapy 1 Carboplatin 1 Audiometry 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ototoxicity × Dexamethasone × Clear all

NCT02382068 2017-11-09

Dexamethasone in Preventing Hearing Loss in Patients Receiving Cisplatin

Ohio State University Comprehensive Cancer Center

Phase NA Withdrawn

Ototoxicity, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡